SGCM
UTHR icon

Sanchez Gaunt Capital Management’s United Therapeutics UTHR Stock Holding History

Sanchez Gaunt Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
3,025
+55
+2% +$31K 0.92% 26
2026
Q1 		$1.76M Buy
+2,970
New +$1.48M 1.1% 22

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sanchez Gaunt Capital Management's UTHR Position: Q2 2026 in Review

Sanchez Gaunt Capital Management increased its United Therapeutics (UTHR) stake by 1.9% in Q2 2026, buying an estimated $31K and bringing the position to 3,025 shares worth $1.64M. The position accounts for 0.92% of the portfolio, ranked #26.

Sanchez Gaunt Capital Management first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.76M in Q1 2026. 873 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Sanchez Gaunt Capital Management held 3,025 shares of United Therapeutics worth $1.64M as of Q2 2026.
  • Sanchez Gaunt Capital Management bought 55 United Therapeutics shares in Q2 2026, an estimated $31K.
  • United Therapeutics made up 0.92% of Sanchez Gaunt Capital Management's portfolio in Q2 2026, its #26 holding.
  • Sanchez Gaunt Capital Management first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Sanchez Gaunt Capital Management's United Therapeutics position peaked at $1.76M in Q1 2026.
  • 873 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Sanchez Gaunt Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.